FIELD: immunology.
SUBSTANCE: present invention relates to immunology. Disclosed are an antibody and its antigen-binding fragment, which specifically binds to ErbB3, as well as a pharmaceutical composition for preventing or treating a disease associated with activation or overexpression of ErbB3 protein. In addition, a method for preventing or treating a disease associated with activation or overexpression of ErbB3 protein and a method for preventing or treating resistance to anticancer drugs are presented.
EFFECT: present invention can find further application in therapy of various types of cancer.
18 cl, 14 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTIBODIES AGAINST AXL AND THEIR APPLICATION | 2011 |
|
RU2577986C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
| NEW ANTIBODY TO CXCR4 AND ITS APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636345C2 |
| ANTIBODIES AND CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO CD19 | 2015 |
|
RU2741105C2 |
| NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
